Kala Pharmaceuticals Inc (NASDAQ:KALA) major shareholder Orbimed Advisors Llc purchased 74,931 shares of the business’s stock in a transaction on Friday, January 19th. The shares were acquired at an average price of $14.95 per share, with a total value of $1,120,218.45. The purchase was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Wednesday, January 24th, Orbimed Advisors Llc purchased 64,637 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $14.91 per share, with a total value of $963,737.67.
  • On Monday, January 22nd, Orbimed Advisors Llc purchased 75,000 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $14.98 per share, with a total value of $1,123,500.00.
  • On Wednesday, January 10th, Orbimed Advisors Llc purchased 170,338 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $12.83 per share, with a total value of $2,185,436.54.
  • On Friday, January 12th, Orbimed Advisors Llc purchased 240,484 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $13.28 per share, with a total value of $3,193,627.52.

Kala Pharmaceuticals Inc (NASDAQ:KALA) traded down $0.13 during trading hours on Wednesday, hitting $14.92. 349,841 shares of the stock were exchanged, compared to its average volume of 470,789. Kala Pharmaceuticals Inc has a 52 week low of $11.81 and a 52 week high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $361.47 and a PE ratio of -8.20.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.14). analysts anticipate that Kala Pharmaceuticals Inc will post -2.22 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of KALA. Victory Capital Management Inc. bought a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $12,414,000. Bank of New York Mellon Corp bought a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $540,000. Commonwealth Equity Services Inc bought a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $360,000. EAM Investors LLC bought a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $1,353,000. Finally, American International Group Inc. bought a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $122,000. Institutional investors own 62.96% of the company’s stock.

KALA has been the subject of a number of analyst reports. Wedbush restated a “buy” rating and set a $46.00 price target on shares of Kala Pharmaceuticals in a research note on Thursday, November 30th. JPMorgan Chase & Co. set a $35.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, November 19th. Wells Fargo & Co restated a “buy” rating on shares of Kala Pharmaceuticals in a research note on Friday, January 5th. BidaskClub upgraded shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 13th. Finally, Zacks Investment Research cut shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Kala Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $36.80.

ILLEGAL ACTIVITY WARNING: “Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 74,931 Shares” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://theolympiareport.com/2018/01/24/kala-pharmaceuticals-inc-kala-major-shareholder-orbimed-advisors-llc-purchases-74931-shares.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Insider Buying and Selling by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.